Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (12150)	6/24/2004 11:08:40 AM
From: quidditch	Read Replies (1) \| Respond to of 52153

KOSN/Roche: Do any of the scientifically enabled have any thoughts on the fundamental news that drove the release, i.e., the toxicity build-up in KOS 862 for the indication that was halted. Is there any reason why toxicity should be different for a colorectal indication than for a prostate indication, or any other? What are the wider implications for the program, and should Roche be re-evaluating the entire relationship, the Needham analyst's comment notwithstanding? There was, I thought, some notion that the epothilone derivatives might be less toxic than other similar meds. quid